Biogen Buys Apellis for $5.6B, Building Immunology Portfolio Ahead of Key Drug Launch

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, gaining two marketed products and a team with nephrology expertise ahead of Biogen's planned felzartamab launch.

The Acquisition

• Acquirer: Biogen
• Target: Apellis Pharmaceuticals
• Value: $5.6 billion
• Key products: Syfovre (geographic atrophy) and Empaveli (PNH)
• CFO Robin Kramer: Deal provides "a team with nephrology expertise valuable for felzartamab launch"

Strategic Rationale

1. Marketed products: Immediate revenue from Syfovre and Empaveli
2. Nephrology expertise: Apellis team's kidney disease experience transfers to felzartamab
3. Portfolio diversification: Reduces dependence on multiple sclerosis franchise
4. CVR structure: Uses Contingent Value Rights to manage deal risk

About the Products

• Syfovre (pegcetacoplan): Treatment for geographic atrophy, an advanced form of age-related macular degeneration
• Empaveli (pegcetacoplan): Treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder

Biotech M&A Wave

This is the second major biopharma acquisition in as many days, following Lilly's $6.3B Centessa deal. Both deals use CVRs, signaling a new M&A paradigm where buyers and sellers share development risk through milestone-linked payments.

Biotech M&A is accelerating in 2026 as large pharma companies seek to replenish pipelines ahead of patent cliffs on key drugs.